Doğu, Gamze Gököz Pamukkale Üniversitesi - Tip Fakültesi - Iç Hastaliklari AD, Tıbbi Onkoloji BD, Turkey , Kargı, Aysegül Denizli Devlet Hastanesi - Medikal Onkoloji Bölümü, Turkey , Yaren, Arzu Pamukkale Üniversitesi - Tip Fakültesi - Iç Hastaliklari AD, Tibbi Onkoloji BD, Turkey , Taşköylü, Burcu Yapar Pamukkale Üniversitesi - Tip Fakültesi - Iç Hastaliklari AD, Tibbi Onkoloji BD, Turkey , Demiray, A.Gökcen Pamukkale Üniversitesi - Tıp Fakültesi - İç Hastalıkları AD, Tıbbi Onkoloji BD, Turkey

The influence of obesity on the recurrence of cancer in HER-2 positive breast cancer patients related to adjuvant trastuzumab treatment

22636

Purpose: Trastuzumab, a humanized monoclonal antibody, was shown to prolong survival in female HER-2 positive early stage breast cancer patients. We examined whether obesity had an influence on the recurrences of HER-2 positive patients, as related to adjuvant trastuzumab treatment, retrospectively. Materials and methods: Among HER-2 positive 170 patients, 129 had accessible data, and with 114, recorded weight / height measurements were statistically analyzed. Results: Of these, the body mass index (BMI) was 30 kg/m2 in 68 (60%), and ≥30 kg/m2 in 46 (40%). Recurrence-free survival (RFS) was 8.8 ± 6.5 and 78.09 ± 12.43 months in the groups with low and high BMI, respectively (p=0.32). Recurrences were found in 7 of 95 (7.4%) receiving Trastuzumab and 13 of 34 patients (38.2%) not receiving. The difference was significant (p 0.001). We detected that 53 patients have a carcinoma insitu on the pathological report (32 patients were BMI 30 kg/ m2 group and 21 patients were BMI ≥ 30 kg/m2 group). Cox regression analysis showed that only presence of carcinoma in situ was significant for PFS, in the population of the study, HR 0.44 (95% CI 1.05-34.28, p=0.044). There was a significant relationship favoring trastuzumab treatment between size of tumor (p=0.04) and hormone receptor positivity with RFS (p =0.002). Moreover, in the hormone receptor negative group, the risk of recurrence was 7.6 folds in the absence of trastuzumab treatment. Median follow-up was 24 months (range 3-257) and recurrence was found in 20 patients (15.5 %). Five patients died during follow-up. Presence of carcinoma-in-situ and use of Trastuzumab had influenced RFS in the population of the study. Rate of hormone receptor negativity was higher and RFS was longer in obese patients than non-obese patients; however, the difference was not significant (p =0.659). Conclusion: Trastuzumab is effective in breast cancer patients to prevent the recurrence, particularly in hormone receptor negative patients.

5

Adjuvant therapy , HER , 2 , breast cancer , trastuzumab , obesity

Pamukkale Medical Journal

11